In recent years, the number of treatments for metastatic, well-differentiated gastrointestinal and pancreatic neuroendocrine tumors (NETs) has expanded significantly.1 New medications for tumor control as well as symptom control include somatostatin analogues, everolimus, sunitinib, telotristat, and lutetium Lu 177 (177Lu)-dotatate. These new therapies have been approved based on randomized clinical trials—an effort that has required international cooperation given the relative scarcity of metastatic NETs.
Strosberg JR, Al-Toubah T, Cives M. Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. JAMA Oncol. Published online February 14, 20195(4):489–490. doi:10.1001/jamaoncol.2018.6694
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: